clinical trial · NCT06497517
A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy Participants
Bellus Health Inc. - a GSK company·phase1·completed·n = 14
CoughGSK5464714- Camlipixant
brief summary
This study is a single center, single dose, open-label, randomly assigned 2-way crossover study. The study will investigate the food effect on the pharmacokinetics of Camlipixant (GSK5464714) in healthy male and female participants. Eligible participants will be randomized to pre-defined sequences. There will be a washout of minimum 7 days between each dose of treatment period.
started
Jul 9, 2024
primary completion
Aug 22, 2024
completion
Aug 26, 2024
last updated
Feb 7, 2025
official title
A Phase 1, Single Center, Single Dose, Open-Label, Randomized, 2-Way Crossover Study to Investigate the Food Effect on the Pharmacokinetics of Camlipixant in Healthy Male and Female Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol